Myomo, Inc. (MYO) Stock Price & Analysis
Myomo, Inc. (MYO) fell 4.24% to USD 1.38 as of September 8, 2026 at 18:39 UTC, according to Nexqual real-time market data.
MYO last closed at USD 1.44; the session ranged USD 1.33–1.46 on volume of 335,491 shares. Market capitalization is $54.62M, with a 52-week range of USD 0.61–1.89 (ASE). Source: Nexqual, September 8, 2026 at 18:39 UTC.
Key Statistics (as of September 8, 2026 at 18:39 UTC)
| Price | USD 1.38 |
|---|---|
| Change | ▼ 4.24% (down) |
| Previous Close | USD 1.44 |
| Open | USD 1.41 |
| Day Range | USD 1.33 – 1.46 |
| 52-Week Range | USD 0.61 – 1.89 |
| Volume | 335,491 shares |
| Market Cap | $54.62M |
| Exchange | ASE |
Technical Analysis (MYO)
Nexqual's technical model rates MYO "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 18:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.5 (neutral) |
| vs SMA50 | Above (USD 1.27) |
| MACD | 0.04 (positive) |
Analyst Ratings (MYO)
Wall Street analysts rate MYO "Strong Buy" based on 5 analysts, with a mean price target of USD 4.64 (range USD 1.7–10.5), per Nexqual as of September 8, 2026 at 18:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.64 |
| High Target | USD 10.5 |
| Low Target | USD 1.7 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (MYO)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $11.51M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.07 vs est -0.1 ▲ beat |
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.09 vs est -0.11 ▲ beat |
Source: Nexqual, September 8, 2026 at 18:39 UTC.
Financials & Fundamentals (MYO)
| Total Revenue | $43.26M |
|---|---|
| Revenue Growth (YoY) | +21.30% |
| Gross Margin | +68.35% |
| Operating Margin | -19.26% |
| Profit Margin | -33.53% |
| ROE | -123.76% |
| Debt / Equity | 344.47 |
| Current Ratio | 2.31 |
| Total Cash | $13.45M |
| Total Debt | $20.08M |
| Free Cash Flow | $-2.41M |
Source: Nexqual, September 8, 2026 at 18:39 UTC.
Financial Health Score (MYO)
Nexqual rates Myomo, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 18:39 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Weak — $13M cash vs $20M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -124%, ROA -19.8% |
Ownership (MYO)
| Insider Ownership | +9.36% |
|---|---|
| Institutional Ownership | +37.89% |
| Shares Outstanding | 39.61M |
| Float | 27.85M |
| Short % of Float | +3.22% |
Source: Nexqual, September 8, 2026 at 18:39 UTC.
Leadership (MYO)
Myomo, Inc. is led by Paul R. Gudonis (age 70), President, CEO & Chairman, per Nexqual as of September 8, 2026 at 18:39 UTC.
| President, CEO & Chairman | Paul R. Gudonis (age 70) |
|---|---|
| Chief Financial Officer | David A. Henry (age 64) |
| Global Director of Operations | Colin Anderson |
| Senior Director of Human Resources | Galina Shtivelman |
| Sr. Director of Clinical Outcomes | Kathy Sawyers |
Major Backers & Investors (MYO)
Notable institutional backers of Myomo, Inc. include Rosalind Advisors, Inc., AQR Capital Management, LLC, Jefferies Financial Group Inc., according to Nexqual as of September 8, 2026 at 18:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.18% |
| AQR Capital Management, LLC | 2.34% |
| Jefferies Financial Group Inc. | 1.78% |
| Jane Street Group, LLC | 1.51% |
| Clearstead Advisors, LLC | 1.07% |
| UBS Group AG | 1.04% |
| LPL Financial LLC | 0.78% |
| Palumbo Wealth Management Llc | 0.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.8% |
| Geode Capital | 0.87% |
Source: Nexqual, September 8, 2026 at 18:39 UTC.
From Myomo, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- During this fitting, the device will be calibrated to the user's individual muscle signal profile using our proprietary software, and adjustments to the brace can be made to optimize fit. • The patient is provided with initial training and a set of take-home tasks to practice with the brace donned.
Partnerships
- In some cases, patients undergo amputation and receive myoelectric prosthetics rather than deal with a paralyzed arm.   Spinal Cord Injuries   According to the Christopher and Dana Reeve Foundation, spinal cord injuries are second only to strokes as a cause of paralysis, resulting in 27% of cases of paralysis.
- We have entered into agreement with O&P providers in the United Kingdom, Denmark, Germany, Italy, and Australia.   Competition   An individual with difficulty walking has a wide range of technological alternatives from canes and crutches to powered wheelchairs and exoskeleton suits.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYSZ | My Size, Inc. | USD 2.14 | ▼ 9.7% |
| MBOT | Microbot Medical Inc. | USD 1.51 | ▲ 4.51% |
| CFOR | CapForce Inc. | USD 5.15 | ▲ 0% |
| PWCM | PowerCompute, Inc. | USD 1.17 | ▼ 6.4% |
| TENX | Tenax Therapeutics, Inc. | USD 2.02 | ▲ 13.2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 18:39 UTC. This page is informational and not investment advice.